LQDA
Liquidia·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LQDA
Liquidia Corporation
A biopharmaceutical company focused on the treatment of pulmonary hypertension (PH)
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
--
Liquidia Corporation was incorporated in Delaware on June 17, 2020. The company is a biopharmaceutical company focused on the development, manufacturing and commercialization of products that address unmet patient needs, with a current focus on the treatment of pulmonary hypertension. The company operates as a single entity through two wholly-owned subsidiaries, Liquidia Technologies and Liquidia PAH. The company conducts research, development and manufacture of new products by applying its expertise in cardiopulmonary disease and proprietary PRINT technology, a particle engineering platform capable of accurately producing uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through product development and research with third parties, the company has experience in applying PRINT to a variety of drug delivery routes and drug payloads, including inhalation therapies, vaccines, biological agents, nucleic acids and ophthalmic implants.
Earnings Call
Q1/2025
Estimate EPS-0.42
Actual EPS-0.45
Estimate Revenue3.23M
Actual Revenue3.12M
Liquidia's Q1 2025 Earnings Call: Unpacking Contradictions on AI Tools, Sales Strategy, and Regulatory Timelines
May 19,2025 09:02
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.39
Actual EPS-0.49
Estimate Revenue3.89M
Actual Revenue8.84M
Liquidia's Q2 2025 Earnings Call: Unpacking Key Contradictions on YUTREPIA's Market Access and Data Presentation
Aug 12,2025 12:49
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LQDA has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.33, beating expectations. The chart below visualizes how LQDA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LQDA has released its 2025 Q3 earnings report, with revenue of 54.34M, reflecting a YoY change of 1121.72%, and net profit of -3.53M, showing a YoY change of 88.61%. The Sankey diagram below clearly presents LQDA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
